Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163184 | 0.82 | LMNA (0.36) | LMNAPDE3BPDE3ASMARCA2SMARCA4 | |
| SCHEMBL19858559 | 0.77 | EPAS1 (0.42) | LMNAPDE3BPDE3A | |
| SCHEMBL18067976 | 0.77 | EPAS1 (0.42) | LMNAPDE3BPDE3A | |
| SCHEMBL19870743 | 0.77 | EPAS1 (0.42) | LMNAPDE3BPDE3A | |
| SCHEMBL19858575 | 0.72 | EPAS1 (0.33) | — | |
| SCHEMBL20315388 | 0.64 | LMNA (0.37) | LMNA | |
| SCHEMBL21362831 | 0.64 | EPAS1 (0.46) | — | |
| SCHEMBL18048340 | 0.63 | LMNA (0.36) | LMNAPDE3BPDE3ASMARCA2SMARCA4 | |
| SCHEMBL19858568 | 0.63 | LMNA (0.36) | LMNAPDE3BPDE3ASMARCA2SMARCA4 | |
| SCHEMBL3435118 | 0.61 | KEAP1 (0.58) | LMNASMARCA2SMARCA4PBRM1SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | LMNA 1126/4885PDE3B 549/4885PDE3A 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.